Quality of life after cancer treatment
With more and more cancer patients surviving long enough to experience the late-term effects of their treatment, the need for continued care and post-treatment “surveillance,” e.g., monitoring for cancer recurrence or other health issues, has increased substantially.
Subsequently, quality of life/survivorship is another CAPOW priority area and one that Fred Hutch is already working to improve. The Survivorship Program, established in 2006 and led by Scott Baker, MD, and Eric Chow, MD, MPH, recently named medical oncologist Vidhya Nair, DO, as its new medical director of Adult Cancer Survivorship.
“We’ve made so many advances in cancer treatments that many patients are being cured and living longer,” Nair explained. “We have to find ways to care for them, not only in terms of monitoring for [cancer] recurrence but also addressing late long-term effects of treatment, including second cancers.”
Survivors have post-treatment psychosocial and sexual health needs, as well, and some may be at high risk for developing cardiovascular disease (CVD), if they received treatment known to cause cardiac effects. Nair said both the risk and the surveillance for CVD depend on the type of treatment, its duration and other risk factors.
“Cardiovascular disease is still the leading cause of death in the U.S.,” she said. “It’s an important comorbidity that can happen in our patients.”
Chow and colleagues, in fact, just published research in JAMA Network Open illustrating the importance of screening cancer survivors for CVD risk after treatment. Chow holds the Jennifer Lynn Kranz, Unravel Pediatric Cancer Endowed Chair at Fred Hutch.
Fred Hutch currently has two long-term follow-up (LTFU) programs, one for people who’ve gone through bone-marrow or stem-cell transplant and another for those who’ve gone through cellular immunotherapy. In addition, any cancer patient can be seen in the Survivorship Clinic by providers like Nair; patients can also get a Survivorship Care Plan, a document that includes their treatment summary, information on potential long-term adverse effects and individualized follow-up recommendations.
Moving forward, a tailored Survivorship program will be embedded into each disease group at Fred Hutch. In breast oncology, for instance, Nair said patients in active treatment (e.g., those going through surgeries, chemo, radiation and other medical therapies) will see their oncologist as well as an APP, or advanced practice provider.
“But once they transition out of active treatment,” Nair said, “they would mostly see an APP, hopefully the same one they were seeing during treatment.”
APPs would continue to monitor these patients for recurrence and address ongoing needs, like managing endocrine therapy side effects. Their oncologists will still be available and involved, as needed, but will mainly focus on newly diagnosed patients just going into treatment. Eventually, patients would transfer their care from survivorship to primary care.
“We’re trying to make the transition from oncology to primary care as smooth as possible,” Nair said. “We want to make sure it’s safe and that we’re addressing these important survivorship topics early on and over the course of time, instead of trying to address it all, say, at one Survivorship Clinic visit.”